GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (NAS:SNDX) » Definitions » Return-on-Tangible-Asset

SNDX (Syndax Pharmaceuticals) Return-on-Tangible-Asset : -49.71% (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Syndax Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Syndax Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2025 was $-339.38 Mil. Syndax Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2025 was $682.76 Mil. Therefore, Syndax Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -49.71%.

The historical rank and industry rank for Syndax Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

SNDX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -76.02   Med: -45.84   Max: 6.64
Current: -58.91

During the past 13 years, Syndax Pharmaceuticals's highest Return-on-Tangible-Asset was 6.64%. The lowest was -76.02%. And the median was -45.84%.

SNDX's Return-on-Tangible-Asset is ranked worse than
64.15% of 1498 companies
in the Biotechnology industry
Industry Median: -37.455 vs SNDX: -58.91

Syndax Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Syndax Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Return-on-Tangible-Asset Chart

Syndax Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.18 6.64 -31.54 -37.72 -47.66

Syndax Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.11 -53.38 -74.55 -65.47 -49.71

Competitive Comparison of Syndax Pharmaceuticals's Return-on-Tangible-Asset

For the Biotechnology subindustry, Syndax Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Return-on-Tangible-Asset falls into.


;
;

Syndax Pharmaceuticals Return-on-Tangible-Asset Calculation

Syndax Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-318.758/( (612.88+724.816)/ 2 )
=-318.758/668.848
=-47.66 %

Syndax Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=-339.384/( (724.816+640.707)/ 2 )
=-339.384/682.7615
=-49.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Syndax Pharmaceuticals  (NAS:SNDX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Syndax Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Syndax Pharmaceuticals Business Description

Traded in Other Exchanges
Address
730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Executives
Michael A Metzger officer: President and COO C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Neil Gallagher officer: President, Head of R&D 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Keith A. Goldan officer: Chief Financial Officer 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Briggs Morrison director, officer: Chief Executive Officer C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
William Meury director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Peter Ordentlich officer: Chief Technology Officer C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Steve M Sabus officer: Chief Commercial Officer 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith Katkin director C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Catherine Madigan officer: Chief Medical Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Alexander Nolte officer: Chief Accounting Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Fabrice Egros director C/O SYNDAX PHARMACEUTICALS, INC., TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Huber Martin H. Jr. director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Daphne Karydas officer: Chief Financial Officer 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451